Albumax Has Been Approved By Medicaid in California &Amp; Pennsylvania
Medivisor, Inc. (PINKSHEETS: MVSR) announced today that Albumax has been approved by the California and the Pennsylvania State Medicaid Offices. Albumax has previously received approval from the New York State Medicaid Office. Albumax has been approved under code B4155 as an enteral product. This approval allows for Medicaid reimbursement of costs for eligible patients using Albumax. Medicaid is the largest source of funding for medical and health-related services for people with limited income. It is an entitlement program that is jointly funded by the states and federal government, and is managed by the states. Among the groups of people served by Medicaid are eligible low-income parents, children, seniors, and people with disabilities.
“These additional Medicaid approvals are extremely important for the national rollout of Albumax,” said Mr. Dino Luzzi, CEO of Medivisor, Inc. “Medicaid acceptance for Albumax increases the willingness of providers and patients to use Albumax to increase blood albumin levels in kidney disorder patients,” continued Mr. Luzzi. Patients and those in the Medical Profession can now go to www.albumax.net to order or inquire about the product.
About Medivisor, Inc.:
Medivisor, Inc. is a developer of next-generation focus driven marketing tools, dedicated to providing technologies that offer innovative and competitive advantages to the bioscience and pharmaceutical markets. From pre-product development through product launch and commercialization, Medivisor offers worldwide experience in delivering effective and successful integrated marketing and creative communications campaigns for the benefit of its clients.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Act”). Additionally, words such as “seek,”"intend,”"believe,”"plan,”"estimate,”"expect,”"anticipate” and other similar expressions are forward-looking statements within the meaning of the Act. Some or all of the events or results anticipated by these forward-looking statements may not occur. Further information on Medivisor risk factors is contained in its filings with the Securities and Exchange Commission. Medivisor does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Contact: Dino Luzzi CEO Medivisor, Inc. Tel: 631.549.7100 Email Contact
SOURCE: Medivisor, Inc.